Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer

Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer. At six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached -   Grade 3/4 neurologic events occurred in 12% of patients; Grade 3/4 CRS occurred in 23% of treated patients using the Penn Grading Scale and was managed by protocol-specific algorithm -   More than a quarter of patients received Kymriah in outpatient setting during JULIET trial -   Cost-effectiveness and societal value of Kymriah in pediatric and young adult patients with r/r B-cell ALL to be presented at ASH The digital press release with multimedia content can be accessed here: -    - Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriah^TM (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The data from this pivotal trial, led by researchers from the University of Pennsylvania (Penn), show an overall response rate (ORR) of 53% (95% confidence interval [CI], 42% - 64%; p <0.0001), with 40% achieving a complete response (CR) and 14% achieving a partial response (PR) among 81 infused patients with three or more months of follow-up or earlier discontinuation.